Next Article in Journal
Study of the Anticancer Potential of Plant Extracts Using Liver Tumor Microphysiological System
Next Article in Special Issue
PHILOS Synthesis for Proximal Humerus Fractures Has High Complications and Reintervention Rates: A Systematic Review and Meta-Analysis
Previous Article in Journal
Taurine Stabilizing Effect on Lysozyme
Previous Article in Special Issue
Major Surgical Trauma Impairs the Function of Natural Killer Cells but Does Not Affect Monocyte Cytokine Synthesis
Article

Inhibition of Pathological Increased Matrix Metalloproteinase (MMP) Activity for Improvement of Bone Regeneration in Diabetes

Department of Plastic and Reconstructive Surgery, BG University Hospital Bergmannsheil, Ruhr-University Bochum, 44789 Bochum, Germany
*
Author to whom correspondence should be addressed.
Academic Editors: Claudia Neunaber, Milena Fini and Paolo Cinelli
Life 2022, 12(2), 134; https://doi.org/10.3390/life12020134
Received: 16 December 2021 / Revised: 12 January 2022 / Accepted: 14 January 2022 / Published: 18 January 2022
(This article belongs to the Special Issue Healing after Trauma)
Patients with diabetes suffer from poor fracture healing. Molecular reasons are not fully understood and our previous gene expression microarray analyses of regenerating bones from mice with type 2 diabetes (db/db) revealed accelerated activation of pathways concerning matrix metalloproteases (MMPs). Thus, we picked out the pathological MMP acceleration as a target for profound gene expression analyses and additional therapeutic intervention in the present study. In the first part, gene expression of ECM degrading proteinases and inhibitors was investigated three and seven days postoperatively. Mmp3, Mmp9, Mmp13 and gene expression of MMP inhibitor Timp2 was significantly higher in regenerating bone fractures of db/db compared to wild type animals. Timp1 and metalloproteinase AdamTS4 showed no differences. In the second part, we locally applied a single dose (1 µL of 5 µM solution) of the broad-spectrum molecular MMP inhibitor Marimastat on tibial defects in db/db. We performed immunohistochemical and histological stainings seven days post operation. Impaired bone healing, collagen content, angiogenesis, and osteoclast invasion in db/db were restored significantly by application of Marimastat compared to PBS controls (n = 7/group). Hence, local intervention of bone defects by the molecular MMP inhibitor Marimastat might be an alternative therapeutic intervention for bone healing in diabetes. View Full-Text
Keywords: bone regeneration; diabetes; gene expression; MMP; Marimastat bone regeneration; diabetes; gene expression; MMP; Marimastat
Show Figures

Figure 1

MDPI and ACS Style

Wagner, J.M.; Reinkemeier, F.; Wallner, C.; Dadras, M.; Dittfeld, S.; Drysch, M.; Sogorski, A.; von Glinski, M.; Lehnhardt, M.; Behr, B.; Becerikli, M. Inhibition of Pathological Increased Matrix Metalloproteinase (MMP) Activity for Improvement of Bone Regeneration in Diabetes. Life 2022, 12, 134. https://doi.org/10.3390/life12020134

AMA Style

Wagner JM, Reinkemeier F, Wallner C, Dadras M, Dittfeld S, Drysch M, Sogorski A, von Glinski M, Lehnhardt M, Behr B, Becerikli M. Inhibition of Pathological Increased Matrix Metalloproteinase (MMP) Activity for Improvement of Bone Regeneration in Diabetes. Life. 2022; 12(2):134. https://doi.org/10.3390/life12020134

Chicago/Turabian Style

Wagner, Johannes M., Felix Reinkemeier, Christoph Wallner, Mehran Dadras, Stephanie Dittfeld, Marius Drysch, Alexander Sogorski, Maxi von Glinski, Marcus Lehnhardt, Björn Behr, and Mustafa Becerikli. 2022. "Inhibition of Pathological Increased Matrix Metalloproteinase (MMP) Activity for Improvement of Bone Regeneration in Diabetes" Life 12, no. 2: 134. https://doi.org/10.3390/life12020134

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop